
MBX Biosciences, Inc.: shareholders and insiders
Price
$53.42
November 18, 2026Market cap $2.5B
What Ploutos Investor adds for MBX Biosciences
Part of Ploutos Investor, €9.99 a month
- The full history: 3 fiscal years, from 2023
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Insiders and their shares
Purchases and sales by officers and directors from Nov 19, 2025 to Nov 12, 2026, from their own Form 4 filings.
Bought on the market
$525.6K
1 person
Sold on the market
$3.0M
3 people
From Nov 19, 2025 to Nov 19, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan89%
- The rest11%
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 19, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·bought $525.6K by 1 person·sold $3.0M by 3 people
- 2025: no buys, no sales
- 2026: bought $525.6K by 1 person, sold $3.0M by 3 people
- Nov 10, 2026Steven L. HoerterChairman, President and CEOKind
- Nov 4, 2026Salomon AzoulayChief Medical OfficerKind
- Aug 4, 2026Salomon AzoulayChief Medical OfficerKind
- Aug 3, 2026John W SmitherChief Financial OfficerKind
- Aug 3, 2026Steven L. HoerterPresident and CEOKind
- May 8, 2026Salomon AzoulayChief Medical OfficerKind10b5-1
- May 8, 2026Salomon AzoulayChief Medical OfficerKind10b5-1
- May 6, 2026P. Kent HawrylukPresident & CEOKind
- May 6, 2026Salomon AzoulayChief Medical OfficerKind
- Mar 13, 2026P. Kent HawrylukPresident & CEOKind
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 10, 2026 | Steven L. HoerterChairman, President and CEO | 4,893 | $54.82 | $268.2K | Form 4 | |
| Nov 4, 2026 | Salomon AzoulayChief Medical Officer | 373 | $53.96 | $20.1K | Form 4 | |
| Aug 4, 2026 | Salomon AzoulayChief Medical Officer | 370 | $65.77 | $24.3K | Form 4 | |
| Aug 3, 2026 | John W SmitherChief Financial Officer | 28.0K | – | – | Form 4 | |
| Aug 3, 2026 | Steven L. HoerterPresident and CEO | 71.0K | – | – | Form 4 | |
| May 8, 2026 | Salomon AzoulayChief Medical Officer | 10b5-1 | 15.0K | $38.30 | $574.6K | Form 4 |
| May 8, 2026 | Salomon AzoulayChief Medical Officer | 10b5-1 | 55.0K | $38.38 | $2.1M | Form 4 |
| May 6, 2026 | P. Kent HawrylukPresident & CEO | 607 | $29.54 | $17.9K | Form 4 | |
| May 6, 2026 | Salomon AzoulayChief Medical Officer | 231 | $29.54 | $6.8K | Form 4 | |
| Mar 13, 2026 | P. Kent HawrylukPresident & CEO | 18.5K | $28.41 | $525.6K | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 5, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by MBX's officers and directors from 2024 up to November 18, 2025, 2 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- FMRwith 1 more personShare of class15.0%
- Frazier Life Sciences Public Fund, L.P.with 7 more personsShare of class11.7%
- Wellington Management Group LLPwith 3 more personsShare of class10.5%
- New Enterprise Associates 17, L.P.with 11 more personsShare of class8.10%
- Orbimed Advisorswith 2 more personsShare of class6.40%
- BlackRock, Inc.Share of class5.50%
- Paradigm BioCapital Advisors LPwith 3 more personsShare of class5.20%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| FMRwith 1 more person | 15.0% | 7.22M | Nov 5, 20263 filings since May 6, 2026 | 13G/A | |
| Frazier Life Sciences Public Fund, L.P.with 7 more persons | 11.7% | 5.24M | Aug 10, 20263 filings since Aug 20, 2025 | 13D/A | |
| Wellington Management Group LLPwith 3 more persons | 10.5% | 4.98M | Jul 8, 20265 filings since May 12, 2025 | 13G/A | |
| New Enterprise Associates 17, L.P.with 11 more persons | 8.10% | 3.62M | Nov 10, 2025 | 13D/A | |
| Orbimed Advisorswith 2 more persons | 6.40% | 3.07M | Aug 10, 20263 filings since Sep 30, 2025 | 13D/A | |
| BlackRock, Inc. | 5.50% | 2.63M | Jul 29, 20263 filings since Jan 21, 2026 | 13G | |
| Paradigm BioCapital Advisors LPwith 3 more persons | 5.20% | 2.49M | Jun 24, 2026 | 13G |
What the holders on a 13D state as their purpose
From Item 4 of the filing, in the holder's own words. It is the intention the holder states, not something that happened.
Frazier Life Sciences Public Fund, L.P.11.7%From the filing of Aug 10, 2026
Item 4 is hereby amended to remove references to "FLSPOF" and the "FLSPOF Shares" from the first paragraph.
From the filing of Aug 10, 2026New Enterprise Associates 17, L.P.8.1%From the filing of Nov 10, 2025
NEA 17 acquired the NEA 17 Shares for investment purposes. Depending on market conditions, its continuing evaluation of the business and prospects of the Issuer and other factors, NEA 17 and the other Reporting Persons may dispose of or acquire additional shares of the Issuer. Except as set forth above, none of the Reporting Persons has any present plans which relate to or would result in: (a) The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (b) An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) A sale or transfer of a material…
From the filing of Nov 10, 2025Orbimed Advisors6.4%From the filing of Aug 10, 2026
The Reporting Persons from time to time intend to review their investment in the Issuer on the basis of various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer's Shares in particular, as well as other developments and other investment opportunities. Based upon such review, the Reporting Persons will take such actions in the future as the Reporting Persons may deem appropriate in light of the circumstances existing from time to time. If the Reporting Persons believe that further investment in the Issuer is attractive, whether because of the…
From the filing of Aug 10, 2026
Fell to 5% or less (4)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Millennium Mgmt (Englander)In the quarter
- Citadel Advisors (Griffin)In the quarter
- D.E. ShawIn the quarter-30%
- AQR CapitalIn the quarter-0.5%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Millennium Mgmt (Englander) | – | – | 0.01% | |
| Citadel Advisors (Griffin) | 7,621 | $400.0K | 0.00% | |
| D.E. Shaw | 127.3K | -30% | $7.5M | 0.00% |
| AQR Capital | 22.5K | -0.5% | $1.3M | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 9.31% of its shares outstanding were held short, -1.0% since the report before.
- Shares held short
- 4.42M
- 9.31%
- Since the report before4.47M on Sep 30, 2026
- -1.0%
- 7.5
- 592.7K
- More days to cover thanof 4,578 US-listed companies with enough volume
- 81%
- Report date
- Oct 15, 2026
- Shares held short
- Sep 30, 2024: Shares held short 363.7K
- Oct 15, 2024: Shares held short 311.8K
- Oct 31, 2024: Shares held short 350.7K
- Nov 15, 2024: Shares held short 345.3K
- Nov 29, 2024: Shares held short 485.2K
- Dec 13, 2024: Shares held short 510.4K
- Dec 31, 2024: Shares held short 1.67M
- Jan 15, 2025: Shares held short 2.03M
- Jan 31, 2025: Shares held short 2.80M
- Feb 14, 2025: Shares held short 3.68M
- Feb 28, 2025: Shares held short 4.11M
- Mar 14, 2025: Shares held short 4.57M
- Mar 31, 2025: Shares held short 5.08M
- Apr 15, 2025: Shares held short 5.36M
- Apr 30, 2025: Shares held short 5.38M
- May 15, 2025: Shares held short 5.29M
- May 30, 2025: Shares held short 4.75M
- Jun 13, 2025: Shares held short 4.65M
- Jun 30, 2025: Shares held short 4.97M
- Jul 15, 2025: Shares held short 4.78M
- Jul 31, 2025: Shares held short 5.34M
- Aug 15, 2025: Shares held short 4.07M
- Aug 29, 2025: Shares held short 3.84M
- Sep 15, 2025: Shares held short 4.23M
- Sep 30, 2025: Shares held short 3.90M
- Oct 15, 2025: Shares held short 3.91M
- Oct 31, 2025: Shares held short 4.58M
- Nov 14, 2025: Shares held short 4.63M
- Nov 28, 2025: Shares held short 4.10M
- Dec 15, 2025: Shares held short 3.61M
- Dec 31, 2025: Shares held short 3.84M
- Jan 15, 2026: Shares held short 2.31M
- Jan 30, 2026: Shares held short 1.97M
- Feb 13, 2026: Shares held short 2.20M
- Feb 27, 2026: Shares held short 2.40M
- Mar 13, 2026: Shares held short 2.98M
- Mar 31, 2026: Shares held short 3.59M
- Apr 15, 2026: Shares held short 3.79M
- Apr 30, 2026: Shares held short 4.03M
- May 15, 2026: Shares held short 4.28M
- May 29, 2026: Shares held short 4.81M
- Jun 15, 2026: Shares held short 5.71M
- Jun 30, 2026: Shares held short 5.90M
- Jul 15, 2026: Shares held short 5.78M
- Jul 31, 2026: Shares held short 5.19M
- Aug 14, 2026: Shares held short 4.95M
- Aug 31, 2026: Shares held short 4.16M
- Sep 15, 2026: Shares held short 4.13M
- Sep 30, 2026: Shares held short 4.47M
- Oct 15, 2026: Shares held short 4.42M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading50.5% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 50.5% of the shares in the reported trades were short sales, against 50.5% in the 14 before.
- Last 14 sessionsOct 30, 2026 – Nov 18, 2026
- 50.5%
- The 14 beforeOct 12, 2026 – Oct 29, 2026
- 50.5%
- Change
- +0.0 pts
- Short sales a dayon average, of 209.1K shares
- 105.6K
- More than atof 3,656 US-listed companies, same days
- 51%
- Median of alleight in ten from 34.4% to 63.7%
- 50.3%
- Short sales
- Oct 12, 2026: Short sales 61.2%
- Oct 13, 2026: Short sales 46.8%
- Oct 14, 2026: Short sales 36.7%
- Oct 15, 2026: Short sales 65.8%
- Oct 16, 2026: Short sales 77.6%
- Oct 19, 2026: Short sales 82.9%
- Oct 20, 2026: Short sales 22.4%
- Oct 21, 2026: Short sales 84.7%
- Oct 22, 2026: Short sales 38.9%
- Oct 23, 2026: Short sales 48.4%
- Oct 26, 2026: Short sales 44.1%
- Oct 27, 2026: Short sales 35.9%
- Oct 28, 2026: Short sales 81.9%
- Oct 29, 2026: Short sales 66.4%
- Oct 30, 2026: Short sales 65.6%
- Nov 2, 2026: Short sales 81.1%
- Nov 3, 2026: Short sales 63.6%
- Nov 4, 2026: Short sales 50.6%
- Nov 5, 2026: Short sales 56.6%
- Nov 6, 2026: Short sales 30.9%
- Nov 9, 2026: Short sales 29.3%
- Nov 10, 2026: Short sales 27.2%
- Nov 11, 2026: Short sales 56.8%
- Nov 12, 2026: Short sales 73.9%
- Nov 13, 2026: Short sales 80.4%
- Nov 16, 2026: Short sales 54.6%
- Nov 17, 2026: Short sales 68.3%
- Nov 18, 2026: Short sales 59.1%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Fhmls X, L.p.TenPercentOwnerDirectly4.55M
- Patrick J HeronDirector,TenPercentOwnerDirectly–
- NEA Partners 17, L.P.TenPercentOwnerDirectly3.61M
- Scott D SandellTenPercentOwnerDirectly–
- Rick YangTenPercentOwnerDirectly–
- Paul Edward WalkerTenPercentOwnerDirectly–
- Mohamad MakhzoumiTenPercentOwnerDirectly–
- Anthony A. Florence Jr.TenPercentOwnerDirectly–
- Carmen ChangTenPercentOwnerDirectly–
- Ali BehbahaniTenPercentOwnerDirectly–
- Forest BaskettTenPercentOwnerDirectly–
- Edward T MathersDirector,TenPercentOwnerDirectly–
- OrbiMed Genesis GP LLCDirector,TenPercentOwnerDirectly–
- Tiba AynechiDirectorDirectly–
- P. Kent HawrylukPresident & CEODirectly727.7K
- Carl L GordonDirector,TenPercentOwnerDirectly–
- Orbimed Advisors LlcDirector,TenPercentOwnerDirectly–
- Steven L. HoerterDirectorDirectly78.0K
- John W SmitherChief Financial OfficerDirectly28.0K
- Ora H. PescovitzDirectorDirectly24.3K
- Salomon AzoulayChief Medical OfficerDirectly14.0K
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Fhmls X, L.p.TenPercentOwner | 4.55M | 5.22M | Sep 26, 2025 | Form 4 |
| Patrick J HeronDirector,TenPercentOwner | – | 4.55M | Sep 16, 2024 | Form 4 |
| NEA Partners 17, L.P.TenPercentOwner | 3.61M | – | Sep 16, 2024 | Form 4 |
| Scott D SandellTenPercentOwner | – | 3.61M | Sep 16, 2024 | Form 4 |
| Rick YangTenPercentOwner | – | 3.61M | Sep 16, 2024 | Form 4 |
| Paul Edward WalkerTenPercentOwner | – | 3.61M | Sep 16, 2024 | Form 4 |
| Mohamad MakhzoumiTenPercentOwner | – | 3.61M | Sep 16, 2024 | Form 4 |
| Anthony A. Florence Jr.TenPercentOwner | – | 3.61M | Sep 16, 2024 | Form 4 |
| Carmen ChangTenPercentOwner | – | 3.61M | Sep 16, 2024 | Form 4 |
| Ali BehbahaniTenPercentOwner | – | 3.61M | Sep 16, 2024 | Form 4 |
| Forest BaskettTenPercentOwner | – | 3.61M | Sep 16, 2024 | Form 4 |
| Edward T MathersDirector,TenPercentOwner | – | 3.61M | Sep 16, 2024 | Form 4 |
| OrbiMed Genesis GP LLCDirector,TenPercentOwner | – | 3.26M | Feb 18, 2025 | Form 4 |
| Tiba AynechiDirector | – | 2.14M | Sep 16, 2024 | Form 4 |
| P. Kent HawrylukPresident & CEO | 727.7K | 486.8K | May 6, 2026 | Form 4 |
| Carl L GordonDirector,TenPercentOwner | – | 747.9K | Feb 18, 2025 | Form 4 |
| Orbimed Advisors LlcDirector,TenPercentOwner | – | 653.8K | Sep 16, 2024 | Form 4 |
| Steven L. HoerterDirector | 78.0K | 20.0K | Nov 10, 2026 | Form 4 |
| John W SmitherChief Financial Officer | 28.0K | – | Aug 3, 2026 | Form 4 |
| Ora H. PescovitzDirector | 24.3K | – | Apr 8, 2025 | Form 4 |
| Salomon AzoulayChief Medical Officer | 14.0K | – | Nov 4, 2026 | Form 4 |
A lower bound: it counts only the 21 officers and directors with a market trade since Nov 20, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- IWCiShares Micro-Cap ETFWeight in the fund0.38%
- IHEiShares U.S. Pharmaceuticals ETFWeight in the fund0.34%
- IBBiShares Biotechnology ETFWeight in the fund0.13%
- FESMFidelity Enhanced Small Cap Core ETFWeight in the fund0.12%
- IWOiShares Russell 2000 Growth ETFWeight in the fund0.10%
- VTWOVanguard Russell 2000 Index FundWeight in the fund0.06%
- IWMiShares Russell 2000 ETFWeight in the fund0.05%
- SCHASchwab U.S. Small-Cap ETFWeight in the fund0.03%
- DFASDimensional U.S. Small Cap ETFWeight in the fund0.03%
- VHTVanguard Health Care Index FundWeight in the fund0.02%
18 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 118
- Q4 2025: Managers 138
- Q1 2026: Managers 157
- Q2 2026: Managers 173
Institutional investors by quarter
The fund managers holding MBX, quarter by quarter, from Q3 2024 to Q2 2025, 4 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 8 quarters.
Q2 2026: 173 managers held 55.48M shares, worth $3.1B. During the quarter 39 opened a position, 23 closed one, 60 added and 47 trimmed.
The largest holders, Q2 2026
- Frazier Life Sciences ManagementIn the quarter
- FMRIn the quarter+81%
- Wellington Management GroupIn the quarter+56%
- NEA ManagementIn the quarter
- Orbimed AdvisorsIn the quarter-5.7%
- BlackRockIn the quarter+13%
- Paradigm Biocapital AdvisorsIn the quarter
- Nvp AssociatesIn the quarter
- Deep Track CapitalIn the quarter-37%
- Polar Capital HoldingsIn the quarter-0.8%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| Frazier Life Sciences Management | 6.65M | $367M | |
| FMR | 5.32M | +81% | $294M |
| Wellington Management Group | 4.98M | +56% | $275M |
| NEA Management | 3.61M | $200M | |
| Orbimed Advisors | 3.43M | -5.7% | $189M |
| BlackRock | 3.32M | +13% | $183M |
| Paradigm Biocapital Advisors | 2.51M | $138M | |
| Nvp Associates | 2.14M | $118M | |
| Deep Track Capital | 1.73M | -37% | $96M |
| Polar Capital Holdings | 1.61M | -0.8% | $89M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do MBX Biosciences's filings show?
Who buys and sells is one part of MBX Biosciences's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have MBX's insiders bought or sold?
From Jun 5, 2026 to Nov 12, 2026 MBX Biosciences's insiders bought 0 and sold $312.7K of shares on the market. 0% of the sales were under set 10b5-1 plans.
Which well-known managers hold MBX?
4 of the managers we track held the shares on Sep 30, 2026. The largest position was D.E. Shaw's, worth $7.5M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.